TY - JOUR
T1 - Insulin-like growth factor I alters peripheral thyroid hormone metabolism in humans
T2 - Comparison with growth hormone
AU - Hussain, Mehboob A.
AU - Schmitz, Ole
AU - Jorgensen, Jens O.L.
AU - Christiansen, Jens S.
AU - Weeke, Jorgen
AU - Schmid, Christoph
AU - Froesch, E. Rudolf
PY - 1996/5
Y1 - 1996/5
N2 - Insulin-like growth factor I (IGF-I) is considered to mediate some of the growth-promoting and metabolic effects of growth hormone (GH). Growth hormone treatment of healthy and GH-deficient subjects is accompanied by increased conversion of thyroxine (T4) to triiodothyronine (T3) in peripheral tissues. Whether these effects are mediated by IGF-I is unknown. To assess the respective roles of these hormones on thyroid hormone metabolism we have treated two groups of subjects. The first group consisted of eight healthy subjects who were treated with IGP-I (10 μg·kg-1· h-1 sc for 5 days). The second group consisted of eight subjects with combined GH and thyrotropin (TSH) deficiency due to acquired pituitary disease. They were treated with IGP-I (10 μg·kg-1·h-1 sc for 7 days), GH (2 IU m-2 sc q.i.d.) or both hormones together. The IGF-I treatment in healthy subjects led to an increase in free T3 (FT3) and a reduction in TSH levels, whereas FT4 and total T4 (TT4) levels remained unchanged. In the second group - in which ail subjects were substituted with oral L-thyroxine - treatment with IGF-I led to an elevation of FT3 in the face of unchanged T4 levels. Growth hormone alone and GH plus IGF-I resulted in a more pronounced elevation in T4 level. The results suggest that IGF-I partially mediates the well-known effects of GH on peripheral conversion of T4 to T3 However, GH has more pronounced effects on thyroid hormones that apparently are not mediated by IGF-I.
AB - Insulin-like growth factor I (IGF-I) is considered to mediate some of the growth-promoting and metabolic effects of growth hormone (GH). Growth hormone treatment of healthy and GH-deficient subjects is accompanied by increased conversion of thyroxine (T4) to triiodothyronine (T3) in peripheral tissues. Whether these effects are mediated by IGF-I is unknown. To assess the respective roles of these hormones on thyroid hormone metabolism we have treated two groups of subjects. The first group consisted of eight healthy subjects who were treated with IGP-I (10 μg·kg-1· h-1 sc for 5 days). The second group consisted of eight subjects with combined GH and thyrotropin (TSH) deficiency due to acquired pituitary disease. They were treated with IGP-I (10 μg·kg-1·h-1 sc for 7 days), GH (2 IU m-2 sc q.i.d.) or both hormones together. The IGF-I treatment in healthy subjects led to an increase in free T3 (FT3) and a reduction in TSH levels, whereas FT4 and total T4 (TT4) levels remained unchanged. In the second group - in which ail subjects were substituted with oral L-thyroxine - treatment with IGF-I led to an elevation of FT3 in the face of unchanged T4 levels. Growth hormone alone and GH plus IGF-I resulted in a more pronounced elevation in T4 level. The results suggest that IGF-I partially mediates the well-known effects of GH on peripheral conversion of T4 to T3 However, GH has more pronounced effects on thyroid hormones that apparently are not mediated by IGF-I.
UR - http://www.scopus.com/inward/record.url?scp=0029896054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029896054&partnerID=8YFLogxK
U2 - 10.1530/eje.0.1340563
DO - 10.1530/eje.0.1340563
M3 - Article
C2 - 8664976
AN - SCOPUS:0029896054
SN - 0804-4643
VL - 134
SP - 563
EP - 567
JO - European journal of endocrinology
JF - European journal of endocrinology
IS - 5
ER -